Details of the Drug

General Information of Drug (ID: DM5XPIJ)

• Drug Name: Leuprolide
• Synonyms: Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1], [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• Sequence:
  >Leuprolide
  PHWSYLLR
• #Ro5 Violations (Lipinski): 4:
  Molecular Weight (mw); 1209.4
  Topological Polar Surface Area (xlogp); 0.7
  Rotatable Bond Count (rotbonds); 32
  Hydrogen Bond Donor Count (hbonddonor); 15
  Hydrogen Bond Acceptor Count (hbondacc); 14
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 4.6 - 212 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4-5 h [3]
  Clearance: The sytemic clearance of drug is 7.6-8.3 L/h [4]
  Elimination: Following administration of 3.75 mg leuprolide depot suspension to three patients, less than 5% of the initial dose was recovered as unchanged or pentapeptide metabolite in the urine.[L10310, L13781, L13784, L13814] [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [4]
  Vd: The volume of distribution (Vd) of drug is 27 L [4]
• Chemical Identifiers:
  Formula: C59H84N16O12
  IUPAC Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
  Canonical SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
  InChI: InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
  InChIKey: GFIJNRVAKGFPGQ-LIJARHBVSA-N
• Cross-matching ID:
  PubChem CID: 657181
  ChEBI ID: CHEBI:6427
  CAS Number: 53714-56-0
  DrugBank ID: DB00007
  TTD ID: D0U5FF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leutinizing-hormone-releasing hormone (GNRH1)	TT0ID4A	GON1_HUMAN	Activator	[2]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 02 Neoplasm
• Disease Class: ICD-11: 2C82 Prostate cancer
• The Studied Tissue: Prostate
• The Studied Disease: Prostate cancer [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leutinizing-hormone-releasing hormone (GNRH1)	DTT	GNRH1	2.23E-01	0.04	0.06

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Leuprolide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[11]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Midostaurin.	Acute myeloid leukaemia [2A60]	[12]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Idarubicin.	Acute myeloid leukaemia [2A60]	[12]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[12]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[12]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Oliceridine.	Acute pain [MG31]	[12]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[12]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Tacrine.	Alzheimer disease [8A20]	[13]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Rivastigmine.	Alzheimer disease [8A20]	[13]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Donepezil.	Alzheimer disease [8A20]	[13]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Leuprolide and Metronidazole.	Amoebiasis [1A36]	[14]
Ranolazine	DM0C9IL	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ranolazine.	Angina pectoris [BA40]	[12]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Bepridil.	Angina pectoris [BA40]	[13]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Dronedarone.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[15]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[12]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Promazine.	Appearance/behaviour symptom [MB23]	[12]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Cilostazol.	Arterial occlusive disease [BD40]	[12]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Voriconazole.	Aspergillosis [1F20]	[12]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Posaconazole.	Aspergillosis [1F20]	[12]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Levalbuterol.	Asthma [CA23]	[16]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Terbutaline.	Asthma [CA23]	[17]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Pirbuterol.	Asthma [CA23]	[17]
Isoetharine	DMITSEH	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Isoetharine.	Asthma [CA23]	[17]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Salbutamol.	Asthma [CA23]	[16]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Formoterol.	Asthma [CA23]	[17]
Atomoxetine	DM5L6HI	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[12]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[12]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[12]
Oxytocin	DMDL27I	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Oxytocin.	Autism spectrum disorder [6A02]	[12]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[12]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[12]
Erythromycin	DM4K7GQ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Erythromycin.	Bacterial infection [1A00-1C4Z]	[12]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[12]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Leuprolide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[13]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[12]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[12]
Moxifloxacin	DMU8V4S	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[12]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[12]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Retigabine.	Behcet disease [4A62]	[12]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Loperamide.	Bowel habit change [ME05]	[20]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Eribulin.	Breast cancer [2C60-2C6Y]	[12]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lapatinib.	Breast cancer [2C60-2C6Y]	[12]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[12]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Toremifene.	Breast cancer [2C60-2C6Y]	[13]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Bosutinib.	Breast cancer [2C60-2C6Y]	[12]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Grepafloxacin.	Bronchitis [CA20]	[18]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Sotalol.	Cardiac arrhythmia [BC9Z]	[13]
Dofetilide	DMPN1TW	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Dofetilide.	Cardiac arrhythmia [BC9Z]	[13]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[12]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Oxaliplatin.	Colorectal cancer [2B91]	[12]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Isoproterenol.	Conduction disorder [BC63]	[16]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Halothane.	Corneal disease [9A76-9A78]	[12]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Propofol.	Corneal disease [9A76-9A78]	[21]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Sevoflurane.	Corneal disease [9A76-9A78]	[12]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Probucol.	Coronary atherosclerosis [BA80]	[12]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Methadone.	Cough [MD12]	[13]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Clofazimine.	Crohn disease [DD70]	[12]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Mifepristone.	Cushing syndrome [5A70]	[13]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Pasireotide.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Osilodrostat.	Cushing syndrome [5A70]	[12]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Sertraline.	Depression [6A70-6A7Z]	[12]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Trimipramine.	Depression [6A70-6A7Z]	[12]
Imipramine	DM2NUH3	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Imipramine.	Depression [6A70-6A7Z]	[12]
Fluoxetine	DM3PD2C	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Fluoxetine.	Depression [6A70-6A7Z]	[12]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Nortriptyline.	Depression [6A70-6A7Z]	[12]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Escitalopram.	Depression [6A70-6A7Z]	[13]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Clomipramine.	Depression [6A70-6A7Z]	[12]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Trazodone.	Depression [6A70-6A7Z]	[12]
Amitriptyline	DMK7F9S	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Amitriptyline.	Depression [6A70-6A7Z]	[12]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Amoxapine.	Depression [6A70-6A7Z]	[12]
Mirtazapine	DML53ZJ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Mirtazapine.	Depression [6A70-6A7Z]	[12]
Protriptyline	DMNHTZI	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Protriptyline.	Depression [6A70-6A7Z]	[12]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Doxepin.	Depression [6A70-6A7Z]	[12]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Maprotiline.	Depression [6A70-6A7Z]	[12]
Venlafaxine	DMR6QH0	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Venlafaxine.	Depression [6A70-6A7Z]	[12]
Citalopram derivative 1	DMITX1G	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Citalopram derivative 1.	Discovery agent [N.A.]	[13]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[12]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Deutetrabenazine.	Dystonic disorder [8A02]	[12]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ingrezza.	Dystonic disorder [8A02]	[12]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Solifenacin.	Functional bladder disorder [GC50]	[12]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Pentamidine.	Fungal infection [1F29-1F2F]	[12]
Fluconazole	DMOWZ6B	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Fluconazole.	Fungal infection [1F29-1F2F]	[12]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ketoconazole.	Fungal infection [1F29-1F2F]	[12]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[12]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[12]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[13]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Crizotinib.	Lung cancer [2C25]	[24]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Ceritinib.	Lung cancer [2C25]	[13]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Osimertinib.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Selpercatinib.	Lung cancer [2C25]	[12]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Lumefantrine.	Malaria [1F40-1F45]	[14]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Halofantrine.	Malaria [1F40-1F45]	[26]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Hydroxychloroquine.	Malaria [1F40-1F45]	[12]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Quinine.	Malaria [1F40-1F45]	[12]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Primaquine.	Malaria [1F40-1F45]	[12]
Mefloquine	DMWT905	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Mefloquine.	Malaria [1F40-1F45]	[12]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[12]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[27]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Vemurafenib.	Melanoma [2C30]	[13]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and LGX818.	Melanoma [2C30]	[12]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Panobinostat.	Multiple myeloma [2A83]	[28]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Thalidomide.	Multiple myeloma [2A83]	[14]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Siponimod.	Multiple sclerosis [8A40]	[14]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Fingolimod.	Multiple sclerosis [8A40]	[13]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Ozanimod.	Multiple sclerosis [8A40]	[29]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Romidepsin.	Mycosis fungoides [2B01]	[12]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[12]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Leuprolide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[30]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Droperidol.	Nausea/vomiting [MD90]	[13]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Prochlorperazine.	Nausea/vomiting [MD90]	[12]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Promethazine.	Nausea/vomiting [MD90]	[12]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Palonosetron.	Nausea/vomiting [MD90]	[12]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Granisetron.	Nausea/vomiting [MD90]	[12]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Ondansetron.	Nausea/vomiting [MD90]	[12]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Entrectinib.	Non-small cell lung cancer [2C25]	[12]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[12]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lofexidine.	Opioid use disorder [6C43]	[12]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Rucaparib.	Ovarian cancer [2C73]	[12]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[12]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Buprenorphine.	Pain [MG30-MG3Z]	[12]
Tramadol	DMRQD04	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Tramadol.	Pain [MG30-MG3Z]	[12]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Triclabendazole.	Parasitic worm infestation [1F90]	[12]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Pimavanserin.	Parkinsonism [8A00]	[12]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Apomorphine.	Parkinsonism [8A00]	[12]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Famotidine.	Peptic ulcer [DA61]	[14]
Vasopressin	DMQ2FPC	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Vasopressin.	Pituitary gland disorder [5A60-5A61]	[12]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[31]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Ritodrine.	Preterm labour/delivery [JB00]	[17]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Alfuzosin.	Prostate hyperplasia [GA90]	[12]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[12]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[12]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[12]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Sorafenib.	Renal cell carcinoma [2C90]	[12]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[19]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Quetiapine.	Schizophrenia [6A20]	[12]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Mesoridazine.	Schizophrenia [6A20]	[13]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Thioridazine.	Schizophrenia [6A20]	[13]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Aripiprazole.	Schizophrenia [6A20]	[14]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Paliperidone.	Schizophrenia [6A20]	[12]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Haloperidol.	Schizophrenia [6A20]	[13]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Perphenazine.	Schizophrenia [6A20]	[12]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Chlorpromazine.	Schizophrenia [6A20]	[12]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Clozapine.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Trifluoperazine.	Schizophrenia [6A20]	[12]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Ziprasidone.	Schizophrenia [6A20]	[13]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Risperidone.	Schizophrenia [6A20]	[12]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Olanzapine.	Schizophrenia [6A20]	[14]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Amisulpride.	Schizophrenia [6A20]	[32]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Asenapine.	Schizophrenia [6A20]	[12]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Pimozide.	Schizophrenia [6A20]	[12]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[12]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[12]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Pitolisant.	Somnolence [MG42]	[12]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[12]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[13]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Leuprolide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[13]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Anagrelide.	Thrombocytosis [3B63]	[13]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Lenvatinib.	Thyroid cancer [2D10]	[12]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Cabozantinib.	Thyroid cancer [2D10]	[12]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Papaverine.	Tonus and reflex abnormality [MB47]	[33]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Tizanidine.	Tonus and reflex abnormality [MB47]	[12]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Tacrolimus.	Transplant rejection [NE84]	[12]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[12]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[12]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[13]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[13]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[12]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Leuprolide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[12]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Leuprolide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[13]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
• [2] Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
• [3] Hoda MR, Kramer MW, Merseburger AS, Cronauer MV: Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28.
• [4] FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use
• [5] Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
• [6] The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623)
• [9] EP patent application no. 2018865, Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate.
• [10] In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8898-902.
• [11] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [12] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [13] Canadian Pharmacists Association.
• [14] Cerner Multum, Inc. "Australian Product Information.".
• [15] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [16] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [17] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [18] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [19] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [20] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [21] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [22] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [23] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [24] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [25] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [26] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [27] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [28] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [30] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [31] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [32] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [33] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]